Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov 1;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015. JAMA Oncol. 2017 Apr 1 [cited 2019 Apr 29] ;3(4):524. Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.5688
   PubMed Web of Science ®Google Scholar
• Breast cancer statistics. Cancer research UK . cited 2019 Apr 29. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer
   Google Scholar
• Comparing more and less developed countries. World cancer research fund . cited 2019 Apr 29. Available from: https://www.wcrf.org/dietandcancer/cancer-trends/comparing-more-and-less-developed-countries
   Google Scholar
• Addressing Cancer Drug Costs and Value - National Cancer Institute . cited 2019 Apr 29. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2018/presidents-cancer-panel-drug-prices
   Google Scholar
• The High Cost of Cancer Treatment- AARP . cited 2019 Apr 30. Available from: https://www.aarp.org/money/credit-loans-debt/info-2018/the-high-cost-of-cancer-treatment.html
   Google Scholar
• Barron JJ, Quimbo R, Nikam PT, et al. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008 May 3 [cited 2019 Apr 30];109(2):367–377. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17674201
   PubMed Web of Science ®Google Scholar
• Campbell JD, Ramsey SD. The Costs of Treating Breast Cancer in the US. Pharmacoeconomics. 2009 [cited 2019 Apr 30];27(3):199–209. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19354340
   PubMed Web of Science ®Google Scholar
• Pallis A, Tsiantou V, Simou E, et al. Pharmacoeconomic considerations in the treatment of breast cancer. Clinicoecon Outcomes Res. 2010 [cited 2019 Apr 29];2:47–61. Available from http://www.ncbi.nlm.nih.gov/pubmed/21935314
   PubMedGoogle Scholar
• Schlosser R. The role of systematic reviews in evidence-based practice, research, and development. Tech Br . 2006 cited 2019 Apr 30;(15). Available from: https://ktdrr.org/ktlibrary/articles_pubs/ncddrwork/focus/focus15/Focus15.pdf
   Google Scholar
• Foster TS, Miller JD, Boye ME, et al. The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev. 2011 Apr [cited 2019 Apr 30];37(6):405–415. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21477928
   PubMed Web of Science ®Google Scholar
• Blank PR, Dedes KJ, Szucs TD. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer. Pharmacoeconomics. 2010 Aug;28(8):629–647.
   PubMed Web of Science ®Google Scholar
• John-Baptiste AA, Wu W, Rochon P, et al. A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer. Miller TW, editor. PLoS One. 2013 May 6 [cited 2019 May 1];8(5):e62614. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23671612
   PubMed Web of Science ®Google Scholar
• Chan AL, Leung HW, Lu C-L, et al. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother. 2009 Feb 3 [cited 2019 Apr 30];43(2):296–303. Available from: http://journals.sagepub.com/doi/10.1345/aph.1L504
   PubMed Web of Science ®Google Scholar
• Zelle SG, Baltussen RM. Economic analyses of breast cancer control in low- and middle-income countries: a systematic review. Syst Rev. 2013 Dec 8 [cited 2019 Apr 30];2(1):20. Available from: https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-2-20
   PubMedGoogle Scholar
• da Costa Vieira RA, Biller G, Uemura G, et al. Breast cancer screening in developing countries. Clinics (Sao Paulo) . 2017Apr [cited 2019 Apr 30];72(4):244–253. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28492725
   PubMed Web of Science ®Google Scholar
• United Nations, New York. World economic situation and prospects 2020. Available from: https://www.un.org/development/desa/dpad/wp-content/uploads/sites/45/WESP2020_Annex.pdf
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• AMSTAR - Assessing the Methodological Quality of Systematic Reviews . cited 2019 Apr 27. Available from: http://amstar.ca/Amstar_Checklist.php
   Google Scholar
• Ofman JJ, Mshs MD. Examining the value and quality of health economic analyses: implications of utilizing the QHES. JMCP J Manag Care Pharm . cited 2019 Apr 30;9(1). Available from: www.amcp.org
   Google Scholar
• Abou Taleb A. Impact of sequencing of treatment lines to enhance patient’s outcomes & resource utilization for metastatic breast cancer. Eur J Cancer. 2018 Apr 1 [cited 2019 Apr 30];92:S110. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0959804918305549
   Web of Science ®Google Scholar
• Nguyen TTC, Nguyen TTT. Cost-utility analysis of trastuzumab in treatment of metastatic her2-positive breast cancer in Vietnam. Value Heal. 2014 Nov 1 [cited 2019 Apr 30];17(7):A643. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1098301514042533
   PubMedGoogle Scholar
• TTC N, TTT N. Cost-effectiveness analysis of 1-year adjuvant trastuzumab therapy of early-stage her2-positive breast cancer. Value Heal. 2014 Nov 1 [cited 2019 Apr 30];17(7):A735. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1098301514020373
   PubMed Web of Science ®Google Scholar
• Garrison LP, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007 Aug 1;110(3):489–498.
   PubMed Web of Science ®Google Scholar
• Shih YCT, Pan IW, Tsai YW. Information technology facilitates cost-effectiveness analysis in developing countries an observational study of breast cancer chemotherapy in Taiwan. Pharmacoeconomics. 2009;27(11):947–961.
   PubMed Web of Science ®Google Scholar
• Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia TT - Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2- positivo en Colombia. Biomédica. 2013;33(3):411–417. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-41572013000300010&lang=pt%0Ahttp://www.scielo.org.co/pdf/bio/v33n3/v33n3a10.pdf
   PubMed Web of Science ®Google Scholar
• Gershon N, Berchenko Y, Hall PS, et al. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Eff Resour Alloc. 2019;17(1):5. Published 2019 Feb 28.
   PubMedGoogle Scholar
• Genuino AJ, Chaikledkaew U, Guerrero AM, et al. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Services Research. 2019;19(1). DOI:10.1186/s12913-019-4715-8
   PubMed Web of Science ®Google Scholar
• Gupta N, Verma RK, Gupta S, et al. Cost effectiveness of trastuzumab for management of breast cancer in India. JCO Glob Oncol. 2020Feb;(6):205–216. doi:10.1200/JGO.19.00293
   PubMedGoogle Scholar
• Fonseca M, Araújo GTB, Saad ED. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil. Rev Assoc Med Bras. 2009;55(4):410–415.
   PubMed Web of Science ®Google Scholar
• Pichon-Riviere A, Garay OU, Augustovski F, et al. Implications of global pricing policies on access to innovative drugs: the case of trastuzumab in seven Latin American countries. Int J Technol Assess Health Care. 2015;31(1–2):2–11.
   PubMed Web of Science ®Google Scholar
• Ansaripour A, Uyl-de Groot CA, Redekop WK. Adjuvant trastuzumab therapy for early HER2-positive breast cancer in iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. Pharmacoeconomics. 2018;36(1):91–103.
   PubMed Web of Science ®Google Scholar
• Chicaíza-Becerra LA, García Molina M, Castañeda C, et al. ErbB2+metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country. Rev Salud Pública. 2015;16(2):270–280.
   Google Scholar
• Aboutorabi A, Hadian M, Ghaderi H, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer. Glob J Health Sci. 2014;7(1):98–106.
   PubMedGoogle Scholar
• Leung HWC, Chan ALF, Muo CH, et al. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer. Expert Rev Pharmacoeconomics Outcomes Res. 2018;18(2):207–213.
   PubMed Web of Science ®Google Scholar
• Chen W, Jiang Z, Shao Z, et al. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Heal. 2009;12(SUPPL.3):S82–4.
   PubMed Web of Science ®Google Scholar
• Ye M, Lu J, Yang F, et al. Economic evaluation of letrozole for early breast cancer in a health resource-limited setting. Biomed Res Int. 2018;2018. DOI:10.1155/2018/9282646
   Web of Science ®Google Scholar
• Lang HC, Chen HW, Chiou TJ, et al. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. J Med Econ. 2016;19(10):923–927.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Clark J, Tu Y, et al. A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget. 2017 Sep [cited 2019 May 1] ;8(42):71548. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29069727.
   PubMedGoogle Scholar
• 衛生福利部中央健康保險署. 2017-2018 National Health Insurance Annual Report. 2017;
   Google Scholar
• Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol. 2014 Apr [cited 2020 Jun 20] ;15(5):489–538. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1470204514700294.
   PubMed Web of Science ®Google Scholar
• Bhoo-Pathy N, Yip CH, Hartman M, et al. Breast cancer research in Asia: adopt or adapt Western knowledge? Eur J Cancer. 2013;49(3):703–709.
   PubMed Web of Science ®Google Scholar
• Hulme C, Hall P, Shinkins B, et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): cost effectiveness analysis results. Abstr B 43rd ESMO Congr . 2018;29:viii703 (ESMO 2018) Munich, Ger.
   Google Scholar
• Miller EM, Schwartzberg LS. Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. Ther Adv Med Oncol. 2019 Nov 14;11. DOI:10.1177/1758835919887044
   Google Scholar
• FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer. FDA . [ cited 2019 Nov 11]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pertuzumab-adjuvant-treatment-her2-positive-breast-cancer
   Google Scholar
• Garrison LP, Babigumira J, Tournier C, et al. Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of her2-positive breast cancer in the United States. Value Heal. 2019 Apr 1 [cited 2019 May 1];22(4):408–415. Available from: https://www.sciencedirect.com/science/article/pii/S1098301519300488
   PubMed Web of Science ®Google Scholar
• Schneider RE, Barakat A, Pippen J, et al. Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer Targets Ther. 2011 Oct;3(3):113–125.
   PubMedGoogle Scholar
• Szabatura AH, Seung AH. Early and Locally Advanced Breast Cancer. ACCP. 2018 [cited 2019 Nov 12]; Available from: www.nccn.org/professionals/
   Google Scholar
• Diaby V, Tawk R, Sanogo V, et al. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 2015 May 19;151(1):27–40.
   PubMed Web of Science ®Google Scholar
• Chapter 1. Pharmacoeconomics: Principles, Methods, and Applications. Pharmacotherapy: A pathophysiologic approach, 8e . AccessPharmacy: McGraw-Hill Medical; [ cited 2019 May 1]. Available from : https://accesspharmacy.mhmedical.com/content.aspx?bookid=462&sectionid=41100767
   Google Scholar
• Räsänen P, Roine E, Sintonen H, et al. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care. 2006 Apr 28 [cited 2019 May 1];22(2):235–241. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16571199
   PubMed Web of Science ®Google Scholar
• Paik H-J, Lee SK, Ryu JM, et al. Conditional disease-free survival among patients with breast cancer. Medicine (Baltimore). 2017 Jan [cited 2019 May 1] ;96(1):e5746. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28072715.
   PubMed Web of Science ®Google Scholar